Jefferies Financial Group Weighs in on Teladoc Health, Inc.’s Q2 2022 Earnings (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC – Get Rating) – Equities research analysts at Jefferies Financial Group dropped their Q2 2022 EPS estimates for shares of Teladoc Health in a report issued on Wednesday, May 4th. Jefferies Financial Group analyst G. Santangelo now forecasts that the health services provider will post earnings per share of ($0.61) for the quarter, down from their prior forecast of ($0.58). Jefferies Financial Group currently has a “Hold” rating and a $82.00 target price on the stock. Jefferies Financial Group also issued estimates for Teladoc Health’s Q3 2022 earnings at ($0.52) EPS, Q4 2022 earnings at ($0.35) EPS, FY2022 earnings at ($1.64) EPS, FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.68) EPS.

Teladoc Health (NYSE:TDOC – Get Rating) last issued its earnings results on Wednesday, April 27th. The health services provider reported ($41.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($41.00). Teladoc Health had a negative return on equity of 2.12% and a negative net margin of 321.94%. During the same quarter in the prior year, the firm posted $0.13 earnings per share.

Several other brokerages have also recently issued reports on TDOC. Credit Suisse Group cut shares of Teladoc Health from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $114.00 to $35.00 in a report on Thursday, April 28th. StockNews.com assumed coverage on shares of Teladoc Health in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Stifel Nicolaus reduced their price objective on shares of Teladoc Health from $83.00 to $74.00 and set a “hold” rating on the stock in a research report on Wednesday, February 23rd. Craig Hallum reduced their price objective on shares of Teladoc Health from $67.00 to $30.00 in a research report on Thursday, April 28th. Finally, Canaccord Genuity Group reduced their price objective on shares of Teladoc Health from $112.00 to $50.00 in a research report on Thursday, April 28th. One analyst has rated the stock with a sell rating, nineteen have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $96.79.

Shares of Teladoc Health stock opened at $33.45 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.48 and a current ratio of 3.94. Teladoc Health has a 52-week low of $28.75 and a 52-week high of $174.32. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of -0.78 and a beta of 0.82. The company’s 50 day moving average price is $61.57 and its 200-day moving average price is $84.71.

Hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC lifted its position in Teladoc Health by 2.9% in the first quarter. ARK Investment Management LLC now owns 19,466,931 shares of the health services provider’s stock worth $1,404,150,000 after purchasing an additional 544,733 shares during the period. Baillie Gifford & Co. lifted its position in Teladoc Health by 23.5% in the fourth quarter. Baillie Gifford & Co. now owns 10,877,063 shares of the health services provider’s stock worth $998,733,000 after purchasing an additional 2,071,756 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Teladoc Health by 17.1% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,140,808 shares of the health services provider’s stock valued at $839,309,000 after acquiring an additional 1,336,508 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its position in shares of Teladoc Health by 18.2% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 8,755,058 shares of the health services provider’s stock valued at $809,843,000 after acquiring an additional 1,349,776 shares during the last quarter. Finally, Kinnevik AB publ acquired a new stake in shares of Teladoc Health during the 4th quarter valued at $458,235,000. 87.17% of the stock is owned by institutional investors and hedge funds.

In other Teladoc Health news, CMO Stephany Verstraete sold 2,858 shares of the business’s stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total transaction of $200,745.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andrew Turitz sold 1,754 shares of the business’s stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total value of $123,200.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,842 shares of company stock valued at $1,042,502. 1.55% of the stock is owned by company insiders.

About Teladoc Health (Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Recommended Stories